These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16928482)

  • 1. Prosthetic heart valves: Objective Performance Criteria versus randomized clinical trial.
    Grunkemeier GL; Jin R; Starr A
    Ann Thorac Surg; 2006 Sep; 82(3):776-80. PubMed ID: 16928482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-related risk of the St. Jude Silzone heart valve.
    Grunkemeier GL; Jin R; Im K; Holubkov R; Kennard ED; Schaff HV
    Eur J Cardiothorac Surg; 2006 Jul; 30(1):20-7. PubMed ID: 16730188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prosthesis-related complications: first-year annual rates.
    Jamieson WR; Burr LH; Anderson WN; Chambers JB; Gams JP; Dowd CM;
    J Heart Valve Dis; 2002 Nov; 11(6):758-63. PubMed ID: 12479275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seven-year results with the St Jude Medical Silzone mechanical prosthesis.
    Jamieson WR; Fradet GJ; Abel JG; Janusz MT; Lichtenstein SV; MacNab JS; Stanford EA; Chan F
    J Thorac Cardiovasc Surg; 2009 May; 137(5):1109-15.e2. PubMed ID: 19379975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA's requirements for in-vivo performance data for prosthetic heart valves.
    Johnson DM; Sapirstein W
    J Heart Valve Dis; 1994 Jul; 3(4):350-5. PubMed ID: 7952304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size requirements for evaluating heart valves with constant risk events.
    Grunkemeier GL; Johnson DM; Naftel DC
    J Heart Valve Dis; 1994 Jan; 3(1):53-8. PubMed ID: 8162217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Silzone effect: how to reconcile contradictory reports?
    Grunkemeier GL; Wu Y
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):371-5. PubMed ID: 15019663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silzone-coated St. Jude Medical valves: six-year experience in 46 patients.
    Dandekar UP; Baghai M; Kalkat M; Ridley PD
    J Heart Valve Dis; 2007 Jan; 16(1):37-41. PubMed ID: 17315381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prosthetic heart valves with silver-coated sewing cuff fabric: early morphological features in two patients.
    Butany J; Scully HE; VanArsdell G; Leask R
    Can J Cardiol; 2002 Jul; 18(7):733-8. PubMed ID: 12167960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new paradigm for obtaining marketing approval for pediatric-sized prosthetic heart valves.
    Yoganathan AP; Fogel M; Gamble S; Morton M; Schmidt P; Secunda J; Vidmar S; Del Nido P
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):879-86. PubMed ID: 23796593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center outcome analysis of 1,161 patients with St. Jude medical and ATS open pivot mechanical heart valves.
    Bernet FH; Baykut D; Grize L; Zerkowski HR
    J Heart Valve Dis; 2007 Mar; 16(2):151-8. PubMed ID: 17484464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic analysis of 19 heart valves with silver-coated sewing rings.
    Butany J; Leask RL; Desai ND; Jegatheeswaran A; Silversides C; Scully HE; Feindel C
    J Card Surg; 2006; 21(6):530-8. PubMed ID: 17073948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized comparison of CarboMedics and St. Jude Medical bileaflet mechanical heart valve prostheses: ten-year follow-up.
    Bryan AJ; Rogers CA; Bayliss K; Wild J; Angelini GD
    J Thorac Cardiovasc Surg; 2007 Mar; 133(3):614-22. PubMed ID: 17320553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a multicenter randomized trial.
    Schaff H; Carrel T; Steckelberg JM; Grunkemeier GL; Holubkov R
    J Heart Valve Dis; 1999 Mar; 8(2):131-9. PubMed ID: 10224570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of implant technique on risk of major paravalvular leak (PVL) after St. Jude mechanical heart valve replacement: a report from the Artificial Valve Endocarditis Reduction Trial (AVERT).
    Englberger L; Schaff HV; Jamieson WR; Kennard ED; Im KA; Holubkov R; Carrel TP;
    Eur J Cardiothorac Surg; 2005 Dec; 28(6):838-43. PubMed ID: 16275007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dysfunctions of heart valve prostheses and their surgical treatment].
    Sadeghi H
    Schweiz Med Wochenschr; 1987 Oct; 117(43):1665-70. PubMed ID: 3321421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian stopping guidelines for heart valve premarket approval studies.
    Grunkemeier GL; Wu Y; Wang L; Hamilton C
    J Thorac Cardiovasc Surg; 2014 Dec; 148(6):2813-7.e1. PubMed ID: 25135236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation and analysis of heart valve substitutes.
    Grunkemeier GL; Anderson WN
    J Heart Valve Dis; 1998 Mar; 7(2):163-9. PubMed ID: 9587856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and severity of paravalvular regurgitation in the Artificial Valve Endocarditis Reduction Trial (AVERT) echocardiography study.
    Dávila-Román VG; Waggoner AD; Kennard ED; Holubkov R; Jamieson WR; Englberger L; Carrel TP; Schaff HV;
    J Am Coll Cardiol; 2004 Oct; 44(7):1467-72. PubMed ID: 15464329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.